Revenue Recognition (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 13, 2022	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Net revenue			$ 67,259	$ 67,257	$ 224,623	$ 265,536
UNITED STATES | Net Product Sales | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration Risk, Percentage			86.00%		93.00%
GIAPREZA
Disaggregation of Revenue [Line Items]
Net revenue			$ 8,000		$ 28,200
XERAVA
Disaggregation of Revenue [Line Items]
Net revenue			5,100		12,100
XACDURO
Disaggregation of Revenue [Line Items]
Net revenue			600		600
GSK
Disaggregation of Revenue [Line Items]
Percentage of royalty payments not entitled to receive	15.00%
Net revenue			53,558	$ 62,150	172,681	$ 260,429
La Jolla
Disaggregation of Revenue [Line Items]
Net revenue		$ 5,100	$ 13,700		$ 40,900
La Jolla | GIAPREZA
Disaggregation of Revenue [Line Items]
Net revenue		3,800
La Jolla | XERAVA
Disaggregation of Revenue [Line Items]
Net revenue		$ 1,300